Perioperative chemotherapy with FLOT improved overall survival in patients with resectable esophageal cancer compared with ...

Patients with advanced non-small cell lung cancer who received palliative care via telehealth had similar improvements in ...

Adding retroperitoneal lymphadenectomy to cytoreductive surgery did not improve survival in advanced ovarian cancer.

The survival benefit obtained from consolidation treatment with durvalumab after concurrent chemoradiation may change the ...

Compared with placebo, osimertinib after definitive chemoradiotherapy improved progression-free survival in locally advanced, ...

Patients with refractory EGFR-mutated, advanced non-small lung cancer had improved responses with low rates of adverse ...

Updated data from the MANIFEST-2 study support a paradigm shift in the treatment of JAK inhibitor–naive patients with ...

A brentuximab vedotin-containing regimen led to “unprecedented” progression-free survival improvements in patients with ...

These data from the COMBI-AD trial represent the longest follow-up to date of adjuvant treatment for stage III melanoma.

Frontline amivantamab plus lazertinib outperformed osimertinib regarding progression-free survival in patients with high-risk EGFR-mutant non-small cell lung cancer. Frontline amivantamab (Rybrevant) ...

Asciminib led to a superior 48-week major molecular response rate compared with investigator-selected tyrosine kinase ...

Lorlatinib, compared with crizotinib, prolonged PFS and improved time to intracranial progression in ALK-positive non–small ...